Jeff H. Lipton

2.1k total citations
41 papers, 1.1k citations indexed

About

Jeff H. Lipton is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Jeff H. Lipton has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 23 papers in Genetics and 11 papers in Oncology. Recurrent topics in Jeff H. Lipton's work include Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (11 papers). Jeff H. Lipton is often cited by papers focused on Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (11 papers). Jeff H. Lipton collaborates with scholars based in Canada, United States and Germany. Jeff H. Lipton's co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, Hans A. Messner, Eric Leip, Suzanne Kamel‐Reid, H. Jean Khoury, Irwin Walker and Dong‐Wook Kim and has published in prestigious journals such as Blood, Cancer and Clinical Infectious Diseases.

In The Last Decade

Jeff H. Lipton

39 papers receiving 1.1k citations

Peers

Countries citing papers authored by Jeff H. Lipton

Since Specialization

Citations

This map shows the geographic impact of Jeff H. Lipton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff H. Lipton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff H. Lipton more than expected).

Fields of papers citing papers by Jeff H. Lipton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff H. Lipton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff H. Lipton. The network helps show where Jeff H. Lipton may publish in the future.

Co-authorship network of co-authors of Jeff H. Lipton

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff H. Lipton. A scholar is included among the top collaborators of Jeff H. Lipton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff H. Lipton. Jeff H. Lipton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant 2021 ·Respiratory Research ·(unknown), (unknown), Jin Ma, L.G. Singer, Jeff H. Lipton, S. Juvet	2
2	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias 2021 ·Leukemia Research ·Vamsi Kota, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, Jeff H. Lipton, Dong‐Wook Kim, (unknown), Eric Leip, Rocco J. Crescenzo, (unknown), Jörge E. Cortes	14
3	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial 2018 ·Blood ·Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, Andreas Hochhaus, Jeff H. Lipton, Vamsi Kota, Michael W. Deininger, Eric Leip, Andrea Viqueira, (unknown), Jörge E. Cortes	9
4	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study 2018 ·Haematologica ·Carlo Gambacorti‐Passerini, Jörge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong‐Wook Kim, Philippe Schafhausen, Rocco J. Crescenzo, Nathalie Bardy‐Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, (unknown), Tim H. Brümmendorf, H. Jean Khoury	44
5	Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients 2017 ·Blood ·Eric A. Coomes, (unknown), Fotios V. Michelis, Dennis Kim, Santhosh Thyagu, Auro Viswabandya, Jeff H. Lipton, Hans A. Messner, (unknown)	7
6	Acute Esophageal Necrosis Complicated by Severe Upper Gastrointestinal Bleeding in Association with Bosutinib Treatment for Chronic Myelogenous Leukemia 2017 ·(unknown), (unknown), Jeff H. Lipton, Michael Beyak	0
7	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Jörge E. Cortes, Carlo Gambacorti‐Passerini, Dong‐Wook Kim, Hagop M. Kantarjian, Jeff H. Lipton, Amit Lahoti, Moshe Talpaz, Ewa Matczak, Elly Barry, Eric Leip, Tim H. Brümmendorf, H. Jean Khoury	40
8	Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib 2016 ·American Journal of Hematology ·Jörge E. Cortes, H. Jean Khoury, Hagop M. Kantarjian, Jeff H. Lipton, Dong‐Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini	68
9	Comparative Efficacy Among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients After Failure Of 2nd Generation Tyrosine Kinase Inhibitors (2G TKIs) 2013 ·Blood ·Jeff H. Lipton, Peter Bryden, Manpreet Sidhu, Hui Huang, Lisa J. McGarry, Stephanie Lustgarten, Beth Woods, Neil Hawkins	0
10	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation 2012 ·Blood ·Jörge E. Cortes, Jeff H. Lipton, Delphine Réa, Raghunadharao Digumarti, Charles Chuah, Nisha Nanda, (unknown), Adam R. Craig, Mauricette Michallet, Franck E. Nicolini, Hagop M. Kantarjian	89
11	Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia 2012 ·Experimental Hematology ·Anna Kreutzman, Taina Jaatinen, Dario Greco, (unknown), Johan Richter, Marja Ekblom, Henrik Hjorth‐Hansen, Leif Stenke, Teresa Pinho e Melo, Ron Paquette, Ruth Seggewiss‐Bernhardt, Agnès Guerci‐Bresler, Alexis Talbot, Jean Michel Cayuela, François‐Xavier Mahon, Kimmo Porkka, Jeff H. Lipton, Jukka Partanen, Philippe Rousselot, Satu Mustjoki	21
12	A non‐invasive oral rinse assay predicts bone marrow engraftment and 6 months prognosis following allogeneic hematopoietic stem cell transplantation 2011 ·Journal of Oral Pathology and Medicine ·(unknown), Guy M. Aboodi, Jeff H. Lipton, Michael Glogauer	9
13	Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years) 2007 ·Leukemia & lymphoma ·Bruno C. Medeiros, Mark D. Minden, Andre C. Schuh, Aaron D. Schimmer, Karen Yee, Jeff H. Lipton, Hans A. Messner, Vikas Gupta, Kathy Chun, Wei Xu, (unknown), Suzanne Kamel‐Reid, Joseph Brandwein	13
14	An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting 2004 ·Biology of Blood and Marrow Transplantation ·Christopher Bredeson, Chantal S. Leger, Stephen Couban, David Simpson, Lothar Huebsch, Irwin Walker, Tsiporah B. Shore, Kang Howson‐Jan, Tony Panzarella, Hans A. Messner, Michael J. Barnett, Jeff H. Lipton	46
15	Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting 2004 ·Cancer Genetics and Cytogenetics ·Hong Chang, (unknown), Rakash Nayar, Dan Li, Suzanne Kamel‐Reid, (unknown), Hans A. Messner, Jeff H. Lipton	9
16	A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets 2002 ·Transfusion ·Nancy M. Heddle, Morris A. Blajchman, Ralph M. Meyer, Jeff H. Lipton, Irwin Walker, Graham D. Sher, (unknown), Bruce Patterson, Robin S. Roberts, Kevin E. Thorpe, Mark N. Levine	158
17	Illness intrusiveness among survivors of autologous blood and marrow transplantation 2001 ·Cancer ·Aaron D. Schimmer, Mary Elliott, Susan Abbey, Lisa Raiz, Armand Keating, Heather Beanlands, Elizabeth McCay, Hans A. Messner, Jeff H. Lipton, Gerald M. Devins	33
18	A Cross‐Canada Survey of Cytomegalovirus Prevention and Treatment Practices in Bone Marrow Transplant Recipients 1999 ·Canadian Journal of Infectious Diseases and Medical Microbiology ·Atul Humar, Jeff H. Lipton, Hans A. Messner, Allison McGeer, Tony Mazzulli	1
19	Effect of Cytomegalovirus Infection on 1‐Year Mortality Rates Among Recipients of Allogeneic Bone Marrow Transplants 1998 ·Clinical Infectious Diseases ·Atul Humar, (unknown), Jeff H. Lipton, Hans A. Messner, J. Meharchand, Allison McGeer, Kelly S. MacDonald, Tony Mazzulli	17
20	Treatment of adults with severe aplastic anemia: Primary therapy with antithymocyte globulin (ATG) and rescue of ATG failures with bone marrow transplantation 1992 ·The American Journal of Medicine ·Michael Crump, Loree Larratt, Ellen Maki, John E. Curtis, Mark D. Minden, J. Meharchand, Jeff H. Lipton, Hans A. Messner	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact